| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 1,890 | 1,412 |
| Gross Profit | 1,673 | 1,216 |
| Pretax Income | 410.36 | 147.16 |
| Net Income | 384.71 | 124.84 |
| Diluted EPS | 0.25 | 0.08 |
- Net Income YoY
- +208.2%
Key highlights
- Quarterly revenue rose to $1,890 million, up from $1,412 million in the prior year
- Net income surged 208.2% year-over-year to reach $384.71 million
- Gross profit margins expanded to 88.5% compared to 86.1% in Q3 2025
- Full-year 2026 revenue guidance was raised to a range of $6.9 billion to $7.0 billion
- Diluted earnings per share increased to $0.25 from $0.08 in the year-ago period
How the Period Went
BeOne Medicines Ltd. achieved a substantial increase in financial performance during the third quarter of 2026. Total revenue reached $1,890 million, representing a 33.9% increase from the $1,412 million reported in the same period of 2025. This top-line growth translated into significant bottom-line gains, as net income rose 208.2% to $384.71 million, compared to $124.84 million in the prior year. Diluted earnings per share followed this upward trajectory, climbing to $0.25 from $0.08. The results indicate a period of rapid scaling, with revenue gains significantly outpacing the prior year's comparative figures.
Margins and Profitability
Profitability metrics for the quarter show enhanced operational efficiency. Gross profit climbed to $1,673 million from $1,216 million, resulting in an improved gross margin of 88.5% compared to 86.1% in Q3 2025. Pretax income saw a sharp rise to $410.36 million from $147.16 million, reflecting improved operating leverage as the company managed increased spending in research and development alongside selling, general, and administrative expenses. This expansion in margins suggests that BeOne Medicines is successfully converting a higher proportion of its product sales into net earnings as its commercial infrastructure and market reach continue to mature.
Business Overview
BeOne Medicines is a biopharmaceutical entity focused on the development and commercialization of innovative oncology treatments. The company serves global markets, providing specialized therapies for hematological malignancies and solid tumors. Its business model relies on a robust pipeline of late-stage clinical candidates, supported by a growing commercial portfolio that drives the majority of its $1.89 billion quarterly revenue. The company recently focused on securing regulatory milestones and expanding its market share in the competitive oncology sector, utilizing an integrated commercial platform to reach healthcare providers and institutional pharmacy networks across several key international markets.
Financial Context
- Quarterly revenue has grown sequentially from $1.51 billion in Q1 2026 to $1.89 billion in Q3 2026 according to SEC filings
- Management raised full-year 2026 revenue guidance on November 5, 2026, to a new range of $6.9 billion to $7.0 billion
- Full-year GAAP operating income is now projected to fall between $1,200 million and $1,300 million per stocktitan.net
- The company maintained a 33.9% year-over-year revenue growth rate, an acceleration from previous fiscal periods
- Profitability has been bolstered by strong product sales volume despite elevated R&D investment for late-stage trials
Industry Landscape
The oncology sector is currently characterized by high demand for targeted therapies and accelerated regulatory cycles. BeOne Medicines’ growth occurs as the industry shifts toward personalized medicine and next-generation inhibitors. The company is positioned against major biopharmaceutical peers competing for dominant shares in the hematology market. A critical upcoming milestone for the firm is the presentation of Phase 3 MANGROVE study data at the 68th ASH Annual Meeting on December 13, 2026. This follows the U.S. FDA’s decision on November 4, 2026, to grant a Priority Review for the company's latest regulatory submission, a status typically reserved for drugs offering significant improvements in treatment.
| Date | Announcement | Amount |
|---|---|---|
| 05 Aug 2026 | Q2 2026 total revenue and raised FY 2026 guidanceSource: SEC filing | $1.71 Billion |
| 06 May 2026 | Q1 2026 total revenue and raised FY 2026 guidanceSource: businesswire.com | $1.51 Billion |
| 26 Feb 2026 | Q4 2025 total revenue and FY 2026 guidanceSource: SEC filing | $1.50 Billion |
| 06 Nov 2025 | Q3 2025 total revenue and FY 2025 guidanceSource: SEC filing | $1.41 Billion |
| 06 Aug 2025 | Q2 2025 total revenue and updated FY 2025 guidanceSource: nasdaq.com | $1.32 Billion |
SEC filing by BeOne Medicines Ltd. announcing its financial results for the quarter ended September 30, 2026.
Track BeOne Medicines Ltd. live
Get the next BeOne Medicines Ltd. SEC filing seconds after it lands.



